leadf
logo-loader
viewIXICO PLC

IXICO plays 'pivotal role' after announcing £2m extension to Huntington's disease study

IXICO PLC's (LON:IXI) Lammert Albers talks to Proactive London about the £2m extension to a contract to provide additional imaging services for a pivotal Huntington's disease (HD) study.

Albers describes this as a 'strong suit' having started very early and now carrying out a Phase III study into a treatment for the disease.

IXICO added the contract will not have a significant performance for the coming year but will add to the company's order book for the year after.

Quick facts: IXICO PLC

Price: 101.5 GBX

AIM:IXI
Market: AIM
Market Cap: £47.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO Plc chief hugely excited by 'really big growth opportunities'

IXICO chief executive Derek Hill caught up with Proactive to discuss the company's full year results and new partnerships. Hill tells Proactive: We're very focused on the brain. Neurodegenerative diseases have been our longer term focus - the perhaps best known one of those - Alzheimer's...

on 11/21/2016

2 min read